Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty.

ABSTRACT:

Introduction

Ovarian cancer (OVCA) has a five-year survival rate of approximately 45%, with little improvement over recent decades. Although anti-PD-L1 therapies have shown substantial efficacy in other solid tumors, their effectiveness in OVCA has been limited. These treatments target only membranous and soluble forms of PD-L1, without addressing nuclear-localized PD-L1. The role of nuclear PD-L1 in OVCA chemoresistance, however, remains largely unexplored. In this study, we examined the prognostic significance of nuclear PD-L1 and its interactions with plasma gelsolin (pGSN) and CD8+ T cells within the tumor microenvironment.

Methods

Using immunofluorescence, we quantified nuclear PD-L1, pGSN, and additional markers in OVCA samples. Statistical analyses and machine learnin

SUBMITTER: Asare-Werehene M 

PROVIDER: S-EPMC12301380 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature